Back HIV Policy & Advocacy

HIV Policy & Advocacy

HIV Glasgow: New $90-$90-$90 Target Needed for Global Viral Hepatitis, HIV, and TB Treatment

The costs of making drugs to treat viral hepatitis, HIV, and tuberculosis (TB) are now so low that each disease could be treated for less than $90, Andrew Hill of St. Stephen’s AIDS Trust said at the opening plenary of the International Congress of Drug Therapy in HIV Infection this week in Glasgow.

alt

Read more:

Donors Pledge $13 Billion to Replenish Global Fund

International donors committed to provide $12.9 billion over 3 years for the Global Fund to Fight AIDS, TB and Malaria at the fund's fifth replenishment conference, held last week in Montreal. "This replenishment is an enormous contribution to our collective ambition of ending AIDS," said UNAIDS executive director Michel Sidibé.

alt

Read more:

FDA Taking Public Comment on Potential Changes to Gay Blood Donation Policy

Through late November the U.S. Food and Drug Administration (FDA) is currently accepting public comments, supported by scientific evidence, as it considers changes to its policy restricting blood donations by gay and bisexual men. Instead of the current 1-year waiting period after a man has sex with another man, the agency is considering a more individualized policy that focuses on risk behavior rather than sexual orientation or self-identification.

alt

Read more:

AIDS 2016: Neglect of Infectious Disease in Prisons Highlighted at Conference

A special issue of The Lancet was published to coincide with the recent 21st International AIDS Conference in Durban, containing a comprehensive seriesof reviews on the burden of HIV, hepatitis B, hepatitis C, and tuberculosis (TB) among prisoners worldwide.

alt

Read more:

AIDS 2016: Earlier HIV Treatment Is Not Over-burdening Health Services

Earlier antiretroviral treatment initiation is not overwhelming rural health services in South Africa, but changes in treatment eligibility criteria alone may not be enough to increase the number of people on treatment substantially, and more investment will be needed in testing and linkage to care to reach treatment coverage goals, research presented at the recent 21st International AIDS Conference (AIDS 2016) shows.

alt

Read more: